Viridian Therapeutics, Inc.
VRDN
$20.99
-$0.82-3.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 305.00K | 302.00K | 302.00K | 302.00K | 288.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 305.00K | 302.00K | 302.00K | 302.00K | 288.00K |
| Cost of Revenue | 330.63M | 300.20M | 301.13M | 222.64M | 222.64M |
| Gross Profit | -330.32M | -299.89M | -300.82M | -222.33M | -222.35M |
| SG&A Expenses | 67.31M | 63.16M | 61.08M | 78.49M | 85.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 371.89M | 337.31M | 299.34M | 283.34M | 251.07M |
| Operating Income | -371.59M | -337.01M | -299.04M | -283.04M | -250.79M |
| Income Before Tax | -344.06M | -308.32M | -269.95M | -257.08M | -228.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -344.06 | -308.32 | -269.95 | -257.08 | -228.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -344.06M | -308.32M | -269.95M | -257.08M | -228.06M |
| EBIT | -371.59M | -337.01M | -299.04M | -283.04M | -250.79M |
| EBITDA | -371.10M | -336.49M | -298.50M | -282.48M | -250.21M |
| EPS Basic | -3.26 | -3.03 | -2.75 | -2.60 | -2.54 |
| Normalized Basic EPS | -2.78 | -2.65 | -2.48 | -2.70 | -2.66 |
| EPS Diluted | -3.26 | -3.03 | -2.75 | -2.60 | -2.54 |
| Normalized Diluted EPS | -2.78 | -2.65 | -2.48 | -2.70 | -2.66 |
| Average Basic Shares Outstanding | 309.41M | 291.67M | 271.43M | 241.06M | 218.29M |
| Average Diluted Shares Outstanding | 309.41M | 291.67M | 271.43M | 241.06M | 218.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |